Unveiling the association between HMG-CoA reductase inhibitors and bladder cancer: A comprehensive analysis using Mendelian randomization, animal models, and transcriptomics
Our study identifies HMG-CoA reductase (HMGCR) inhibitors, particularly simvastatin, as potential agents for reducing bladder cancer (BLCA) risk, and provides potential insight for clinical practice for BLCA treatment or adjuvant therapy.
Mutation in Bruton Tyrosine Kinase (BTK) A428D Confers Resistance To BTK-Degrader Therapy In Chronic Lymphocytic Leukemia
Drugs that target BTK for proteasomal degradation, so-call BTK degraders, are presumed able to mitigate the risk of drug resistance due to BTK mutations. In Leukemia 38:1818 (2024), Kipps and colleagues describe a patient who developed resistance to the BTK-degrader BGB-16673 via a mutation in BTK.
AAV-CXCL9 Combination Immunotherapy: A Promising Strategy in the Treatment of Glioblastoma
Investigators at the University of Florida Brain Tumor Immunotherapy Program developed a novel immunotherapy combining AAV gene therapy and anti-PD-1 immune checkpoint blockade to overcome immune suppression in glioblastoma.
Tepotinib in Asian patients with METex14 skipping NSCLC
VISION, the largest study of a MET inhibitor for rare NSCLC with METex14 skipping mutations, shows tepotinib's efficacy and safety in Asian patients align with overall results. It provides the first health-related quality of life assessment for this group, supporting once-daily tepotinib treatment.